Iran’s Nuclear Program Is Framed as the Legacy of Strategic State Support
Atomic Energy Organization chief Mohammad Eslami attributes Iran’s nuclear advances to long-term leadership, institutional development and reliance on domestic capabilities.
IRNA reports that Atomic Energy Organization chief Mohammad Eslami attributed Iran’s nuclear advances to long-term political guidance, institutional development and domestic scientific capacity. He cited achievements in nuclear electricity, radiopharmaceuticals, agriculture and medical technology, while defending enrichment and alleging sustained foreign pressure. Most quantitative, technical and geopolitical claims in the account are statements by Eslami and are not independently verified in the supplied evidence.
In a televised interview reported by IRNA on July 7, 2026, Mohammad Eslami, head of Iran’s Atomic Energy Organization, presented the country’s nuclear industry as the outcome of sustained political direction, institutional investment and support for scientific development. He credited the late leader referred to in the report as the “martyred Imam” with prioritizing advanced technologies, creating the institutions needed to develop them and encouraging young researchers to participate in national projects.
Eslami linked this strategic approach to several areas of Iran’s nuclear program. He said national policy had long included the expansion of nuclear power, research into fusion energy and the development of a domestic fuel cycle, including enrichment. He also argued that enrichment was essential to the production of medical radioisotopes, describing it as part of a broader chain supporting healthcare rather than as an isolated technical activity.
The interview highlighted both power generation and non-energy applications. Eslami cited the Bushehr nuclear plant’s reported production of 80 billion kilowatt-hours of electricity and claimed that this output had avoided the consumption of more than 130 million barrels of oil. He also said Iran was pursuing a 20,000-megawatt nuclear electricity target by 1420 in the Iranian calendar, with additional facilities planned in several provinces. These figures and project timelines were presented by Eslami and are not independently substantiated in the supplied material.
According to the account, the organization has approximately 80 radioisotopes in its product portfolio, used by about 1.5 million people annually, and has advanced domestically produced radiopharmaceuticals into commercial distribution. The report also described nuclear and plasma technologies used or being developed for agricultural irradiation, medical-equipment sterilization, cancer and wound treatment, seed improvement, reduction of agricultural waste and water and soil treatment. Claims about clinical effectiveness, productivity gains and export activity likewise rely on Eslami’s statements.
A central theme of the interview was resistance to external pressure. Eslami alleged that Iran’s nuclear sector had faced sanctions, industrial sabotage, attacks on scientists, political restrictions and obstacles to international cooperation. He argued that these pressures demonstrated the strategic importance of nuclear technology and reinforced the need for self-reliance. The source does not provide independent documentation for the specific incidents or legal assessments mentioned.
The interview therefore functions primarily as an official narrative about Iran’s nuclear development rather than as an independently verified assessment of program performance. Its main argument is that technological progress depends on political prioritization, institutional capacity and sustained investment in domestic scientific expertise. The broader claims concerning economic returns, medical outcomes, agricultural benefits, international nuclear expansion and the motives of foreign governments require corroboration from technical, economic or international sources.